Hemostemix Inc. (CVE:HEM – Get Free Report) shares shot up 37.9% during trading on Thursday . The company traded as high as C$0.24 and last traded at C$0.20. 1,160,600 shares traded hands during trading, an increase of 120% from the average session volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Stock Performance
The business’s 50 day simple moving average is C$0.09 and its 200-day simple moving average is C$0.07. The company has a market cap of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- There Are Different Types of Stock To Invest In
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Investing In Automotive Stocks
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MarketBeat Week in Review – 01/06 – 01/10
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
